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Randomised comparison of fluorouracil, epidoxorubicin and methotrexate
(FEMTX) plus supportive care with supportive care alone in patients with
non-resectable gastric cancer
S Pyrhonen', T Kuitunen', P Nyandotol and M Kouri'
Departments of'Radiotherapy and Oncology and 'Clinical Pharmacology, Helsinki University Central Hospital, Helsinki, Finland.
Smimary A phase III randomised study, comparing treatment with fluorouracil. epidoxorubicin and
methotrexate (FEMTX) with the best cupportive care, was conducted in patients with unresectable or
metastatic gastric cancer. During the period from July 1986 to June 1992, 41 patients were randomised to
receive FEMTX or best supportive care. MTX was given in a dose of 1500mgm-2 intravenously (i.v.)
followed after 1 h by 5-FU 1500 mg m-2 i.v. on day 1; leucovorin rescue was started after 24 h (30 mg orally
every 6 h for 48 h) and epidoxorubicin 60 mg m-2 i.v. was administered on day 15. In addition both groups
received tablets containing vitamins A and E. Response rates for FEMTX were as follows: complete response
(CR), 19% (4/21); partial response (PR), 10% (2j21); no change (NC), 33% (7'21); and progressive disease
(PD). 24% (5'21). Response rates in the control group were: NC, 20% (4/20); and PD, 80% (16 20). Increased
pain was observed in one patient in the treated group and in 11 patients in the control group within the first 2
months. WHO grade HI/IV toxicity in the chemotherapy group was as follows: nausea/vomiting 40%,
diarrhoea 10%, stomatitis 15%, leucopenia 50% and thrombocytopenia 10%. One possible treatment-related
death was due to sepsis. The median time to progression in the FEMTX group was 5.4 months [95%
confidence interval (CI) 3.1-11.7 months], but only 1.7 months in the control group (95% CI 1.2-2.7 months)
(P = 0.0013). Similarly, the FEMTX group displayed significantly (P = 0.0006) prolonged survival compared
with the control group, i.e. median survival 12.3 months (95% CI 7.1-15.6 months) vs 3.1 months (95% CI
1.6-4.6 months). In conclusion, FEMTX combined with vitamin A and E is a fairly well-tolerated treatment,
giving a response rate of 29% in patients with advanced gastric cancer, and also prolonging patients' survival.
It can be used as a reference treatment in testing new investigational combinations.
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Treatment of gastric cancer remains a great challenge. At
diagnosis, 75% of patients have disseminated disease
(Dupont et al., 1978). Even among the subgroup of patients
able to undergo potentially curative resection, relapse is com-
mon. Because 5 year survival ranges from 10% to 15% of all
patients with newly diagnosed disease, the use of chemo-
therapy in patients with gastric cancer has been the subject of
great interest.
At present, four drugs have been identified as exhibiting
modest or moderate single-agent activity in patients with
advanced gastric cancer. These drugs are 5-fluorouracil (5-
FU), adriamycin, mitomycin and cisplatin. During the late
1970s a FAM (fluorouracil, adriamycin, mitomycin) regimen
composed of these active drugs was widely adapted as a
routine treatment for advanced gastric cancer, although no
controlled trials supported its routine use. In fact, in a com-
parative study between 5-FU and 5-FU plus adriamycin or
FAM, no difference in survival between the treatment groups
was observed (Cullinan et al., 1985).
During the last decade a new, promising cancer regimen
has been reported using the technique of biochemical modu-
lation of 5-FU. Klein et al. (1983) developed the regimen of
high-dose methotrexate (MTX), high-dose 5-FU and adria-
mycin with leucovorin rescue, called FAMTX. The first
report on this combination described a response rate as high
as 63% (Klein et al., 1983). Since then, in different studies, a
total of 364 patients have received FAMT`X, with a cumula-
tive response rate of 41% (Kelsen et al., 1992).
Although the response rates using these new drug com-
binations are considerably higher than with 5-FU alone, no
definitive proof exists as to whether these treatments have
any real impact on patients' survival, nor does there exist any
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such study on 5-FU. To elucidate this issue, we performed a
randomised tnral in which patients were assigned to receive
either chemotherapy (FEMTX) plus trace amounts of
vitamin A and E or the same vitamins and best supportive
care only. In this study we replaced adriamycin with epi-
rubicin for reasons discussed later. The main focus of this
study was to analyse whether this chemotherapy regimen can
change the natural course of advanced gastric cancer, thus
prolonging patients' survival.
Patients and methods
Patients
During the period from July 1986 to June 1992, 41 patients
with histologically confirmed gastric cancer were entered into
this study. During the study period five other patients were
eligible for this study but refused to take part in the ran-
domisation. The patients were randomised by a sealed
envelope method. Random permutated blocks (length 10)
were used. The block was not known by clinicians. Patients
were not stratified by any pretreatment characteristics.
Criteria for patient eligibility included: age 75 years or
younger, no previous chemotherapy or radiation therapy,
Karnofsky performance status of 60% or greater and ade-
quate bone marrow functions as defined by leucocyte count
4000jA' and platelet count 100000 O l'. Each patient
also had to have acceptable renal and hepatic function
(serum creatinine level <l5O moll-', total serum bilirubin
level <40gumol 1'), and serum albumin was required to be
> 30 g 1-'. All patients had to have measurable or assessable
tumour, either an inoperable primary or metastatic gastric
cancer. Measurable disease included delineated tumour
masses on physical examination, routine radiography or com-
puterised tomographic or ultrasound scans. Before entering
the trial, oral informed consent was obtained.S. *'hn eta
Treatment
Patients were randomised to receive either chemotherapy or
symptomatic treatment, i.e. best supportive care including
trace amounts of vitamins A and E. In the treatment arm,
MTX was given in a dose of 1500mgm-2 intravenously (i.v.)
followed after 1 h by 5-FU 1500mgm-2 i.v. on day 1;
leucovorin rescue was started after 24 h (30mg orally every
6h for 48 h) and epirubicin 60 mgmr2 i.v. was adminisered
on day 15. Optimal hydration (diuresis > 100 mlh-'), allka-
linisation of the urine before administering MTX and
monitoring of the plasma MTX lvel were performed. In
cases of elevated MTX, the leucovorin dose was adjusted.
Cycles were repeated every 4 weeks. Patients in the control as
well as in the chemotherapy arm received tablets containing
vitamins A (retinol palmitate, coresponding to 3000 IU of
vitamin A) and E (70mg of£-tocopherol acetate) three times
a day. The main indication for use of vitamins was to
increase motivation of control group patients -to visit
regulary and to undergo control examinations. Supportive
care consisted ofanalgesics, nutritional support, blood trans-
fusions to correct severe anaemia and psychological support.
Palliative surgery to relieve obstruction could also be per-
formed.
Assessment ofresponse and toxicity
Prior to randomisation, evaluation included a complete his-
tory and physical examination and determination of blood
counts (haemoglobin, leucocytes, platelets), blood alkaln
phosphatase, serum bilirubin and serum albumin. Serum
creatinine and creatinine clarance were also measured. In
the treatment group blood counts were checked prior to
every drug administration, and the other laboratory values
were obtained every 4 weeks.
Response was evaluated by clinical examination, with lung
radiographs taken every 4 weeks, and, when applicable com-
puterised tomography scans or ultrasound every 8 weeks.
Responses were evaluated according to International Union
Against Cancer (UICC) criteria (Hayward et al., 1977). Com-
pete response (CR) was defined as the disappearance of all
signs of disease for at least 4 weeks; partial response (PR) as
at least a 50% reduction in the sum of the products of the
greatest perpendicular diameters of the measurable lesions
without an increase in size of any lesion, or any appearance
of new lesions; stable disease (SD) as less than a PR in the
absence of disease progression for at least 8 weeks;, and
disease progression (PD) as an increase of at least 25% in the
sum of products of the largest perpendicular diameters of
measurable lesions or the development of new lesions. The
evaluation of adverse effects followed World Health Organ-
ization (WHO) guidelines (Miller et al., 1981).
Responses to important symptoms such as pain were
requested at every 4 week control visit. Patients who did not
come to the first control visit owing to deterioration of
general condition and early death were ineligible for this
analysis.
Statisticalanalysis
It was estimated that the trial would be able to accrue ten
patients per year with histologically confirmed non-resectable
gastric cancer. Based on studies reported in literature, the
expected I year survival of the control group was about
10%. In order to detect a 25%i.mprovement of FEMNTX
therapy (1 year survival 35%), at a = 0.05 (one-sided) and
80% 'power', a sample size of 52, halfrandomly assgned to
each arm, was estmated to be n . Allowing for a 10%/.
loss to follow-up, the final sample size was calculated to be
60.
For calculation of tim to progression and overallsurvival
from the day of randomisation, product-limit survival ana-
lysis was performed. Allpatients randomised were included
in these analyses. Calculations of the significnceofobserved
differences were performed using the log-rank test (Peto et
al., 1977). All P-values are two-tailed.
Relts
Until June 1992, 41 patients were randomised in the study.
Initially the study was to be conducted at the Department of
Radiotherapy and Oncology as well as at the Second Internal
Medicine Department of Heisink-i University Central Hos-
pital. During the first 3 years of the study the Internal
Medicine Department could randomise only four patients
into this trial; after that time this unit subsequently aban-
doned randomisation. Thus, this study was finally conducted
in one clinical unit. During the study one patient randomised
to no chemotherapy was treated with an out-patient schedule
of doxorubicin, sequential methotrexate and 5-fluorouracil
(Pyrh6nen and Valtonen, 1990). This decision was made by
the patient's doctors. No other patient from the control
group received any chemotherapy.
The pretreatment characteristics of the patient populations
are shown in Table I. Twelve patients (five in the FEMTX
group and seven in the control group) had locally recurrent
or metastatic disease after radical operation. The median
time (range) from orginal diagnosis to randomisation in the
FEMTX and control group, respectively was 67 (15-124)
weeks vs 55(29-182) weeks in relapsed patients and 7(1-17)
weeks vs 8 (5-13) weeks in newly diagnosed patients. As can
be seen, the two groups were well balanced as to the usual
prognostic criteria, including age, Karnofsky performance
status, weight loss, proportion of symptomatic patients
(weight loss was not included as a symptom), extent of
disease, metastatic sites and prior surgery. Slightly more male
patients were randomised into the FEMTX arm.
Response
In the treatment group 20 patients received at least one
course ofchemotherapy. One patient never received the study
drugs owing to some disturbance of renal function observed
after randomisation. The median number of adminiser
chemotherapy courses was 5, and at most two patients
received up to 12 courses. Among all the randomised patients
in the FEMTX arm, there were six responders (29%), four
complete and two partial (Table I). In addition, seven
patients experienced disease stabilisation longer than 2
months. The duration of the four complete responses was
5.5, 8.3, 15 and 38.2 + months, and the duration of two
partial responses 10.5 and 16.2 months. Of four complete
responders, three patients have suffered a relapse, and two of
them have died. The fourth patient still maintains CR. In the
control group receiving only vitamins and best supportive
care, four patients exhibited stabilised disease for more than
2 months; all the other patients had disease progression.
Pain was the most frequent symptom complained ofby the
patients. Thirty-even patients (19 in the chemotherapy group
and 18 in the control group) were eligible for analysis ofpain
during the first 2 months. Nime patients in the chemotherapy
group and eight ofthe control patients complained ofpain at
the beginning of the study. During the next 2 months pain
disappeared in three cases and remained unchanged in five
cases, only one patient had progression ofpain in the treated
group. Thus only 6 out of 19 evaluable patients had mainly
mild pain (four grade I, one grade II and one grade Ill) at
1-2 months in the treated group. In contrast, in the control
group aggravation ofpain was remarkable in 11 of 18 evalu-
able patients within 2 months. Seven patients who did not
have pain at the beginning complained of pain, and in four
other cases pain had become worse. Thus, at 1-2 months 15
out of 18 evaluable patients in the control group displayed
pain of variable intensity (five grade I, three grade H, four
grade HI and three grade IV). Further comparson of pain
was not possible, sinc the majority of the patients in the
control group died within 4 months.
Timetoprogression andsurvival
In the FEMTX group, the median time to progression was
5.4 months (95% CI 3.1-11.7 months) vs only 1.7 monthsFEMTX vss.ppa cminpasOrcanr
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(95% CI 1.2-2.7 months) in the control group (P<0.0013).
This difference is illustrated in Figure 1. Similarly, a highly
significant difference (P<0.0006) was detected in median
survival between the two study groups. The FEMTX group
displayed median survival of 12.3 months (95% CI 7.1-15.6
months), while the control group had a median survival of
only 3.1 months (95% CI 1.6-4.6 months). This remarkable
difference is shown in Figure 2. The 1 year survival rate in
the treated group was 52%, and the 2 year survival rate was
24%, while 1 and 2 year survival rates were 5% in the
control group.
At September 1992, 3 months after the last randomisation,
five patients were alive, all of these in the FEMTX group,
while all of the control patients had died. A highly significant
difference (P<0.001, two-sided) in survivals was detected,
favouring the treatment group. Owing to slow patient accrual
and the conspicuous difference in patient survival, further
randomisation was abandoned at this point. At the close of
this analysis, May 1994, two patients in the FEMTX group
were still alive, 65 + and 26 + months from the randomisa-
tion. The 65-month survivor was still in CR without any
evidence of disease progression.
Toxicity
Twenty patients in the FEMTX group were evaluable for
toxicity. Eight patients (40%) experienced grade III/IV
nausea and vomiting (Table III) which could be better
ameliorated during the last 2 years of the study with new
antiemetic drugs. Three patients (15%) had fairly disturbing
stomatitis, and two of these and a third patient also had
peeling of the skin, mainly from palmar and plantar areas.
The main haematological toxicity was leucopenia: ten
patients (50%) had grade III/IV leucopenia and two (10%)
Table I Patient characteristics
FEMTX
(n =21)
(years) 58 (42-75)
15:6
Karnofsky performance status
100
90
80
60-70
Weight loss
None or <10%
>10%
Symptomatic
Non-symptomatic
Extent of disease when the
diagnosis was made
Stage I-IIH
Stage IV
Advanced disease of primary
phase/recurrent disease
Median diameter of largest
tumour mass (range) (cm)
Locoregional/metastatic
Sites of metastatic disease8
Liver
Lymph nodes
Subcutaneous
Peritoneum
Lung
Other
Prior surgery
Biopsy only
Explorative laparotomy
Palliative
Curative
4
11
4
2
12
9
14
7
7
14
16/5
Control Control
(n = 20)
58 (42-71)
10:10
3
10
5
2
14
6
13
7
5
135
13/7
100
0
0
4 0 04
0
C. 0
OD 20
a.
0
0 6 12 18
Months
24 30 36
Fiwe 1 Progression-free time in the FEMTX (0) and control
groups (@).
1
5.0 (2-13) 5.5 (2-12)
6'15
7
15
4
4
1
5
3
3
10
5
6,14
8
13
1
2
0
3
3
9
7
aMany patients had more than one site of metastases.
CD
C.)
0
a-)
0
0 6 12 18 24 30 36
Months
Fuwe 2 Overall survival of the FEMTX (0) and control
groups (0).
Tablk H Responses
FEMTX Control
n (%) n (%)
CR 4 (19) 0 (0)
PR 2 (10) 0 (0)
NC 7 (33) 4 (20)
PD 5 (24) 16 (80)
NpE 3 (14) 0 (0)
Total 21 20
aNE, non-evaluablefor response (onepatient died early, evidently as a
result of toxicity of the treatment; a second patient never received the
study drugs owing to disturbance of renal function observed after
randomisation; in thethird case tumour measurements were not reliable
enough to define the response).
Tabek m Side-effects` (WHO grade) of the FEMTX regimen
WHO grade
0 1 2 3 4
ChniCalb
Diarrhoea 15 0 3 2 0
Nausea/vomiting 3 7 2 7 1
Stomatitis 12 2 3 3 0
Laboratory'
Hb 6 9 4 1 0
Leucopenia 4 2 4 6 4
Thrombocytopenia 17 1 0 1 1
Renal disturbance 19 1 0 0 0
SThe worst toxicity observed over all cycles. bTwenty patients treated
with FEMTX and evaluable for side-effects.
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Mean age (range) (
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grade Ill[IV thrombocytopenia. Chemotherapy was stopped
in one patient because ofgrade I renal toxicty. One possibly
treatment-related death, due to sepsis, was registered. For
comparison, eight cases of grade I anaemia evidently asoi-
ated with disease and one case of grade H euopenia were
observed in the control group. No subjecive side-effects or
renal or hepatic toxicity were reported as a result of the
vitamin treatment.
Paliative measues
We have carefully analysed all the palliative measures in the
two study groups. FEMTX chemotherapy required hospital-
isation for 2-3 days every month during the treatment
period. Many of the patients had pain at first presentation.
In the chemotherapy group pain was either releved or un-
changed, while the majority of the control patients experi-
enced aggravation of pain within 2 months. Consequently,
the use of analgesics by treated patients was unged or
reduced and by control patient was increased. No sgnificnt
differences in in-patient treatment or other supportive
measures such as nutritional support, psychologial support
or blood trnsfusions could be demonstrated between the
two arms. Two patients (one from each study group) under-
went palliative surgery within 12 months of randomisation,
one because of intestinal obstruction (control patient) and
the other because of rupture of the gastric wall (FEMTX
patient). Between 12 and 24 months another two surviving
patients in the FEMTX group underwent palliative surgery
for gastrointestinal obstruction.
During recent years some successes have been achieved with
combination chemotherapy regimens such as FAMTX, EAP
(etoposide, doxorubicin, cisplatin), ELF (etoposide,
leucovorin, 5-FU) and ECF (epirubicin, cisplatin, 5-FU) in
the treatment of advanced gastrc cancer. With these
regImes objective remission rates of more than 50% have
been reported, including approximately 10% complete remis-
sions (Wldke et al., 1990; Fmdlay and Cunningham, 1993;
Cocconi, 1994; Ellis and Cunningham, 1994). Some of these
CRs have even been confirmed histopathologically.
In spite of promisg high response rates achieved with
these drug combinations, it has been unclear until now
whether these favourable responses can be translted into
prolonged survival. This study was initiated because all
previous studis on gastric cancer involving a new drug or
drug combination have compared results with results in
patients treated with some other drug(s) or drug combina-
tion(s). In most of the previous studies the comparison group
has comprised patients treated with 5-FU alone. However,
there have been no randomised comparative stui on 5-FU
relating 'natural' outcome of the disease to that of patients
treated with the best supportive care only, without any
chemotherapy.
As a treatment schedule, we sekld a slightly modified
course of FAMTX, a regimen reported to yield one of the
highest response rates. The reason for substituting 60mgm-2
epirubicin for 30mgm-2 doxorubicin as tbe anthracyclin
component ofthe scheme derived, firstly, from the knowledge
that epirubicin is a less toxic drug with the same efficacy as
doxorubicin. Secondly, we received information that the
EORTC Gastrointestinal Tract Cooperative Group was plan-
ning a large comparative study of FEMTX and FAM
regimens. We therefore decided to perform our comparative
study using the same regimen. Later, however, it emerged
that the EORTC study group had substituted the original
FAMTX regimen introduced by Klein (Wils et al., 1991). In
fact, the International Cooperative Cancer Group (ICCG) is
currently using FEMTX as a reference treatment in com-
parison with FEMTX-P, with the addition of cisplatin (P)
(Wils, 1992). The aim of this study is to evaluate more
precsely the role of cisplatin added to this high-dose MTX-
bsed
Previous experiences with FEMTX in gastric cancer are
imited to one phase II study with a response rate of 37%
(Wils et al., 1990). An in vitro study even suggests that in
similar concentrations gastric cancer cells may be more sen-
sitive to epirubicin than to adriamycin (Kohnoe et al., 1992).
Ifthis observation could be transferred to a clinical situation,
our sekction of epirubicin, with a doubled dose of adria-
mycin compared with the orginal FAMTX regimen, might
offer patients some advantage. Furthermore, using the same
drugs with different scheduling also seems to be effective in
patients with advanced colorectal cancer (Pyrh6nen and
Kouri, 1992).
Although the number of patients in this study is limited,
our observations do confirm the fact that sequentially
adminliered high-dose MTX and 5-FU, combined with the
anthracyclin epidoxorubicin, is a highly active drug combina-
tion in advanced gastric cancer, not only in terms of objec-
tive responses but also in retarding disease and pain progres-
sion and prolonging patients' survival. Unfortunately, this
study had to be stopped even before the targeted number
(60) of patients was achieved, mainly because of slow patient
accrual and the withdrawal of the second original research
unit from the study. The analysis, however, made more than
6 years after initiating the study, demonstrated a conspicuous
difference in overall survival between the chemotherapy-
treated group and the control group. It was thus considered
unethical to continue this study. This decision was further
supported by the fact that all five patients who were alive at
that time were in the chemotherapy-treated group, four of
these having achieved a complete response as a result of the
treatment.
In comparing the response rate ofour patients treated with
the FEMTX regimen, the results are similar to the combined
data on FAMTX. The response rate calculated for all the
randomised patiets (including one patient who never receiv-
ed the drugs) m the present study was 29%, while the
cumulative response rate for FAMTX involving 364 treated
patients has been reported to be 41% (Kelsen et al., 1992).
The median overall survival of the present study, 12.3
months (95% CI 7.1-15.6 months), although slightly longer
than in most of the FAMTX studies, was in the same range
as in those studies. Nor did the median overall survival of3.1
months (95% CI 1.6-4.6 months) for the control group
differ remariably from expectations of the natural course of
advanced gastric cancer without chemotherapy. Historically,
in some reports median survival of patients without chemo-
therapy has been reported to range from 3 to 4 months
(Moertel, 1968). After a detailed comparison, the conclusion
is that no difference in patient characteristics or any suppor-
tive measure except chemotherapy can explain the difference
in survival in the two study groups.
Interestingly, a recent study by Murad et al. (1993) demon-
strates very similar observations to our results. In that study
patients were randomised to a modified version of FAMTX
or best supportive care. In the middle of the study the
randomisation was also interrupted because of strong
evidence of benefit in the treatment arm. Further patients
were accrued to the treatment arm, and by the end of the
study 30 evaluable patients had recoived chemotherapy and
ten supportive treatment only. The median overall survival
time of the treated group was 10 months, and that of the
control group only 3 months (P= 0.001).
The accumulating data now support the view that in
patients with locally advanced or metastatic gastric cancer
prolongation of survival can be achieved by treatment with
chemotherapy. The particular combination used in this study
seems to be of most interest. In a comparative trial by the
EORTC study group, treatment with FAMTX resulted in
sigificantly longer median survival than and similar toxcity
as the widely used FAM regimen (Wlds et a!., 1991). Another
study compared FAMTX with a promising regimen EAP
(Kelsen et al., 1992). Randomisation of this study had to be
interrupted soon after 60 patients were colleted, 30 in eachFMTX Pssupporli care mipSolo cancer
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treatment arm, since the EAP combination demonstrated
significantly more severe toxicity, including four treatment-
related deaths, and the response rate was slightly lower
among patients receiving EAP than among those receiving
FAMTX.
Although regimens such as FAMTX or FEMTX are still
far from the optimum when the aim is cure, they can be used
as comparative treatments in new developmental approaches.
These combinations should also be further explored in new
therapeutic strategies for gastric cancer such as pre- (Kelsen
et al., 1994) or perioperative chemotherapy.
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